Free tool
FAERS Monitor: Serostim
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 020604 or its brand name (Serostim, Somatropin). Reports on generic versions are filed under their own applications.
Reports
6,707
Serious
4,702
70% of reports
Hospitalization
1,615
Death reported
482
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use446
- device leakage334
- headache252
- injection site pain224
- drug dose omission by device219
- death211
- fatigue191
- drug ineffective155
- device mechanical issue150
- arthralgia142
- device issue137
- product dose omission issue135
- pyrexia133
- nausea125
- sleep apnoea syndrome123
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 48 |
| 2005 | 25 |
| 2006 | 37 |
| 2007 | 122 |
| 2008 | 59 |
| 2009 | 224 |
| 2010 | 174 |
| 2011 | 214 |
| 2012 | 225 |
| 2013 | 103 |
| 2014 | 186 |
| 2015 | 272 |
| 2016 | 385 |
| 2017 | 300 |
| 2018 | 310 |
| 2019 | 485 |
| 2020 | 415 |
| 2021 | 314 |
| 2022 | 485 |
| 2023 | 795 |
| 2024 | 715 |
| 2025 | 479 |
| 2026 | 335 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,452 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| device mechanical issueSignal | 150 | 34.7 | 29.6 | 4,822 |
| device leakageSignal | 334 | 24.3 | 21.9 | 7,409 |
| sleep apnoea syndromeSignal | 123 | 20.3 | 17.1 | 2,230 |
| drug dose omission by deviceSignal | 219 | 8.8 | 7.7 | 1,506 |
| device issueSignal | 137 | 4.8 | 4.1 | 409 |
| injection site painSignal | 224 | 2.3 | 2.0 | 164 |
| off label use | 446 | 1.6 | 1.5 | 103 |
| product dose omission issue | 135 | 1.4 | 1.2 | 18 |
| headache | 252 | 1.3 | 1.1 | 14 |
| pyrexia | 133 | 1.2 | 1.0 | 5 |
| arthralgia | 142 | 1.1 | 0.9 | 1 |
| fatigue | 191 | 0.8 | 0.7 | 13 |
| death | 211 | 0.8 | 0.7 | 15 |
| nausea | 125 | 0.5 | 0.4 | 66 |
| drug ineffective | 155 | 0.4 | 0.3 | 178 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.